Emerging markets 2020 mid-year outlook China plus one strategy

The COVID-19 outbreak gives an impetus to diversify the China supply chain and Southeast Asia and India are potential beneficiaries here

01 Jul 2020

Many companies are however looking at a ‘China plus one’ strategy …
South-East Asia and India are potential beneficiaries of the ‘plus one’ strategy, and we’ll likely see more reshoring to North America, Korea or Japan.

Geoffrey Wong, Head of Emerging Markets and Asia-Pacific Equities

Subscribe now

Perspectives matter. Tune in to our insights.

While the attention of the COVID-19 pandemic moves away from China, businesses are slowly resuming, but will China and EM continue to be global growth hotspots, and is investment in China still too big an opportunity to ignore? We take an in-depth look at the pace of recovery in Emerging Markets (EM) and explore whether the economic recovery is a roadmap for the West.

Some observers may draw parallels between COVID-19 and SARS, but the current pandemic is much more significant because of its severity and geographical spread, due mainly to the fact that world is now much more interconnected. Additionally, China is now a much more significant part of the world economy than it was before.

As we write, it is difficult to predict the shape of a COVID-19 recovery since a lot depends on how both the outbreak evolves and how the search for preventions and cures progresses. As such, this is likely to be a story that continues into next year.

But at a time when new cases, treatments and policies drive a global news cycle, the challenge for forward-looking investors is to focus on what matters. With that in mind, here are eight takeaways on our current view and the future outlook for EM equities:

Over the years, the composition of EM has shifted towards domestic sectors like consumption, e-commerce, and financial services, and away from more global sectors like energy and materials, thus making EM less exposed to a global downturn than they were during both the Global Financial Crisis and the SARS outbreak. However, the crisis this time is more global and the economic hit is larger. Countering this is the unprecedented amount of fiscal and monetary policy support globally.

Changes between 2008 and 2019 in MSCI Industry groups

The MSCI EM benchmark weighting have changed between 2008 and 2019, and consumer sectors are much larger

On the whole, EM company balance sheets have been improving since the Asian financial crisis in 1997/1998 and are more defensive, especially when compared to the US and Europe. That said, we may see a temporary increase in leverage in the coming months as EM companies work through the crisis period.

Net debt/equity, 1996-2019

Emerging Markets companies have much lower debt levels than other global regions

Governments across EM have stepped up with wide-ranging policy support.

On the monetary side, central banks in eleven EM countries cut rates in April (China, India, South Africa, Russia, Mexico, Poland, Turkey, Philippines, Peru, Colombia, and Pakistan). This has been possible because most countries in the EM space have maintained a prudent policy mix so far with respect to their real rates, and had room to cut rates.

On the fiscal front, governments are stepping up their efforts too. Russia for instance stated that the govern­ment plans to allocate ~3% of its GDP to fight the pandemic.

Even prior to COVID-19, the move to reduce global dependence on the China supply chain had started, driven by rising costs in China and rising automation reducing labor cost differentials, the trade conflict and tariffs, and a general desire to diversify China risk.

COVID-19 provides an additional impetus to diversify from the China supply chain.

Many companies are however looking at a ‘China plus one’ strategy, hence China will likely continue to be both an important production base and final market for companies. South-East Asia and India are potential beneficiaries of the ‘plus one’ strategy, and we’ll likely see more reshoring to North America, Korea or Japan.

COVID-19-induced changes in behavior have accelerated the shift from offline to online services, benefiting business segments like after-school tutoring, financial services, and healthcare diagnosis.

Companies are also stepping up investment in R&D and innovation, and there is growing demand for automated solutions. Additionally, the COVID-19 outbreak is spurring consolidation within many industries both in China and EM more widely.

At the time of writing, Chinese equities¹ have outperformed US² and European³ equity markets YTD. We see three reasons for this: firstly, China made a decisive, successful response in controlling the outbreak and this gave investors confidence; secondly, China moved quickly and showed strong capacity to stimulate and support the economy and, finally, US equities started the year being much more expensive than China.

Additionally, China is showing signs of being one of the first economies to move toward a recovery, with a widespread relaxation of pandemic controls coming in early May and data on intra-city traffic and coal consumption showing incremental improvements over recent weeks.

Finally, the COVID-19 crisis has been a very good test of the standalone China thesis. China’s equity market remains under-represented in global equity indices. Also, the correlation between domestic China and other equity markets remains low and this was again proven during this crisis.

The COVID-19 crisis has been a very good test of the standalone China thesis.

For all the disruption to everyday life from COVID-19, we don’t see a meaningful impact on the long-term drivers that underpin EM.

Demographic trends within EM aren’t going to change because of the pandemic; the population of working age people in EM is still expected to grow 0.81%, on average, per year between 2020 and 2050, while it will decline 0.3% per year in developed markets.

This demographic change is significant because it means that the world’s new working population and consumer bases will come from EM and support domestic demand growth. And as incomes rise in EM, consumers are shifting their wallet share towards discretionary consumption and better quality goods and services.

EM went into this crisis with inexpensive valuations and are now trading around 1.5 price/book –meaningfully lower than their historic average of around 1.8 – and EM currencies are close to historic lows on a real effective exchange rate basis.

Looking over the past twenty years, EM equities have tended to recover quickly after key outflow periods such as the SARS outbreak in 2002, and the Global Financial Crisis of 2008/2009.

Current valuations could make for nice entry points from a long-term perspective.

So while it is difficult to predict the possibility and shape of a second COVID-19 wave, we are focused on companies that can withstand at least 12 months of very difficult conditions in terms of balance sheet and cash flows.

In terms of changes to our portfolio, we have reduced our exposure to banks across a number of countries. We like this sector structurally, but banks in many countries face near-term headwinds as they bear the brunt of the economic slowdown.

We have added to our positions in the internet and e-commerce sectors, especially outside Asia. Consumer and IT remain our key exposures both on absolute terms as well as relative to the index. We tend to be fully invested but continue to look for opportunities to rotate into potential long-term winners at appropriate price points.

Mid-year outlook 2020 A short, sharp shock or prolonged pain?

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.